One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Digital health interventions in chronic kidney disease: levelling the playing field?
Matthew P M Graham-Brown, Alice C Smith, Sharlene A Greenwood
doi : 10.1093/ckj/sfac259
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 763–767
Digital health interventions (DHIs) have long been thought of as a convenient way to deliver aspects of healthcare and broaden access to services. For patients with chronic kidney disease (CKD), DHIs designed to improve health literacy, self-efficacy and health-related behaviours such as physical activity, diet and adherence have been developed and are being tested, but their translation into clinical practice will be challenging.
The hypokalaemia that came from the cold
Mohamed E Elsayed, Benedikt Schick, Alexander Woywodt, Biff F Palmer
doi : 10.1093/ckj/sfad036
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 768–772
While electrolyte disorders are common in nephrologists’ clinical practice, hypothermia is a condition that nephrologists rarely encounter. Hypothermia can induce several pathophysiological effects on the human body, including hypokalaemia, which is reversible with rewarming.
Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival
Clara GarcÃa-Carro, Kenar D Jhaveri, Ben Sprangers
doi : 10.1093/ckj/sfad035
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 773–775
In the last decade, immune checkpoint inhibitors (ICI) have become a cornerstone in the treatment of a wide range of malignancies. It is well established that ICI are associated with multiple immune-related adverse events, a spectrum of autoimmune toxicities, that can also affect the kidney.
Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefined
Steven Fishbane, Deepa A Malieckal, Ji H Ng
doi : 10.1093/ckj/sfad026
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 776–779
With the emergence of hypoxia inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs) came the hope that using these oral drugs could improve the treatment of the anemia of kidney disease. In this editorial we discuss the accumulated knowledge on these agents and the clinical context for use.
Practical approaches to building up a cardiorenal clinic
Rafael de la Espriella, Marta Cobo Marcos, Claudio Ronco, Debasish Banerjee, Miguel González, José Luis Górriz, Borja Quiroga, MarÃa José Soler, Javier DÃez, Julio Núñez
doi : 10.1093/ckj/sfac258
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 780–792
The population with concomitant heart and kidney disease (often termed ‘cardiorenal’ disease) is expected to grow, significantly impacting public health and healthcare utilization.
Should we CLICK on chlorthalidone for treatment-resistant hypertension in chronic kidney disease?
Should we CLICK on chlorthalidone for treatment-resistant hypertension in chronic kidney disease?
doi : 10.1093/ckj/sfac272
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 793–796
Treatment-resistant hypertension is common among patients with advanced chronic kidney disease (CKD). In people with preserved kidney function, spironolactone is an evidence-based treatment. However, the risk for hyperkalemia limits its use in people with more advanced CKD.
Tirzepatide and prevention of chronic kidney disease
Catalina Bosch, Sol Carriazo, MarÃa José Soler, Alberto Ortiz, Beatriz Fernandez-Fernandez
doi : 10.1093/ckj/sfac274
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 797–808
Tirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes mellitus (T2DM). More specifically, tirzepatide is an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP1) receptors.
Frailty assessment as part of transplant listing: yes, no or maybe?
Mara A McAdams-DeMarco, Amarpreet K Thind, Andrew C Nixon, Alexander Woywodt
doi : 10.1093/ckj/sfac277
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 809–816
Frailty, characterized by a decreased physiological reserve and an increased vulnerability to stressors, is common among kidney transplant (KT) candidates and recipients. In this review, we present and summarize the key arguments for and against the assessment of frailty as part of KT evaluation.
The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Mehmet Kanbay, Sidar Copur, Dimitrie Siriopol, Abdullah Burak Yildiz, Metehan Berkkan, Raluca Popa, Nuri Baris Hasbal, Alberto Ortiz, Mark A Perazella
doi : 10.1093/ckj/sfac194
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 817–826
Immune checkpoint inhibitors (ICPIs) are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, we assessed the effect of AKI on mortality outcomes in cancer patients receiving this immunotherapy.
Serum potassium changes during hypothermia and rewarming: a case series and hypothesis on the mechanism
Khaled Boubes, Daniel Batlle, Tanya Tang, Javier Torres, Vivek Paul, Humaed Mohammed Abdul, Robert M Rosa
doi : 10.1093/ckj/sfac158
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 827–834
Hypokalemia is known to occur in association with therapeutically induced hypothermia and is usually managed by the administration of potassium (K+).
Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
Frida Welander, Henrik Renlund, Emöke Dimény, Henrik Holmberg, Anders Själander
doi : 10.1093/ckj/sfad004
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 835–844
The use of direct oral anticoagulants (DOAC) in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD) including dialysis is growing. Several studies have shown favorable results of DOAC compared with warfarin regarding bleeding risk but no difference in stroke protection.
The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis
Kullaya Takkavatakarn, Theerachai Thammathiwat, Jeerath Phannajit, Pisut Katavetin, Kearkiat Praditpornsilpa, Somchai Eiam-Ong, Paweena Susantitaphong
doi : 10.1093/ckj/sfac271
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 845–858
Renal anemia in chronic kidney disease (CKD) is associated with poor outcomes. Hypoxia-inducible factor (HIF) stabilizer, which induces endogenous erythropoietin synthesis and enhances iron mobilization, is a novel treatment for anemia in CKD. We conducted a systematic review and meta-analysis to analyze the effect of HIF stabilizers in anemic CKD patients.
Practical implementation and clinical benefits of the new automated dialysate sodium control biosensor
Francisco Maduell, José J Broseta, Diana RodrÃguez-Espinosa, Joaquim Casals, Victor Escudero, Miquel Gomez, Lida M Rodas, Marta Arias-Guillén, Manel Vera, Néstor Fontseré
doi : 10.1093/ckj/sfad013
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 859–867
A key feature of dialysis treatment is the prescription of dialysate sodium (Na). This study aimed to describe the practical implementation of a new automated dialysate Na control biosensor and to assess its tolerance and the beneficial clinical effects of isonatraemic dialysis.
A small circulating miRNAs signature predicts mortality and adverse cardiovascular outcomes in chronic hemodialysis patients
Davide Bolignano, Marta Greco, Pierangela Presta, Anila Duni, Caterina Vita, Ethymios Pappas, Maria Mirabelli, Lampros Lakkas, Katerina K Naka, Antonio Brunetti, Daniela Patrizia Foti, Michele Andreucci, Giuseppe Coppolino, Evangelia Dounousi
doi : 10.1093/ckj/sfad017
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 868–878
Chronic hemodialysis (HD) patients exhibit severe morpho-functional cardiac alterations, putting them at a high risk of death and adverse cardiovascular (CV) outcomes. Despite the fact that an unbalanced expression of various microRNAs (miRNAs) has been related to pathological cardiac remodeling and worse CV outcomes, scarce evidence exists on their role in this setting.
Comparison of four medium cut-off dialyzers
Detlef H Krieter, Christoph Wanner
doi : 10.1093/ckj/sfad002
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 879–880
Reply to “Comparison of four medium cut-off dialyzers�
Francisco Maduell, José Jesús Broseta, Maria del Carmen Salgado, Nayra Rico
doi : 10.1093/ckj/sfad001
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Pages 881–882
Correction to: Triglycerides–glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease
doi : 10.1093/ckj/sfac255
Clinical Kidney Journal, Volume 16, Issue 5, May 2023, Page 883
